By Connor Hart
Shares of iSpecimen gained after securing suppliers for the flu-like human metapneumovirus, a virus which causes upper respiratory infections.
The stock rose 22%, to $3.50, in after-hours trading Thursday. Shares ended the regular session 8% higher, at $2.85, putting them down 71% over the last year.
The online marketplace for human biospecimens said the virus has been causing hospitals in China to become overrun, and that it has raised concerns of another public-health pandemic.
"There is currently no vaccine for HMPV, hence the potential need for samples if a company were looking to make this type of breakthrough drug or study the virus," iSpecimen said in a Securities and Exchange Commission filing.
It added the potential demand for a vaccine for the virus highlights the need for reliable access to high-quality specimens.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
January 16, 2025 18:19 ET (23:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。